Perform Another (Advanced) Search

1.  Study Posting (4519) Trial #153878, Breast Cancer, Edinburgh, United Kingdom
...cancer Brief Summary: This 2 part study will explore the pharmacodynamic effects of R1507 in breast cancer tumor cells in female patients with operable breast cancer. In the first part of the ...
View Page

2.  Study Posting (4519) Trial #153912, Breast Cancer, Bournemouth, United Kingdom
...cancer Brief Summary: This 2 part study will explore the pharmacodynamic effects of R1507 in breast cancer tumor cells in female patients with operable breast cancer. In the first part of the ...
View Page

3.  Newly Approved Drug Therapies (46) Arimidex (anastrozole), AstraZeneca,
...gain reported with progestins. Mechanism of Action Results from studies suggest that growth of some breast cancer tumors is stimulated by the female hormone estrogen. Arimidex, a nonsteroidal compound, is the first ...
View Page

4.  Study Posting (4694) Trial #83471, Breast Cancer, Poughkeepsie, NY
...You may be eligible to participate in this trial if: • Stage 0, I or II breast cancer. Tumor size must be 3.0 cm or less. • Diagnosis of Ductal Carcinoma in Situ ...
View Page

5.  CenterWatch: List of Newly Approved Drug Thearapies
...Novartis; Treatment for acute organ transplant rejection, Approved May 1998 Xeloda ; Roche; Treatment for advanced breast cancer tumors, Approved April 1998 Zemplar ; Abbott Laboratories; Treatment of secondary hyperparathyroidism associated with chronic renal ...
View Page

6.  Study Posting (4519) Trial #121567, Breast Cancer, Zaragoza, Spain
...frame: Throughout study Inclusion Criteria: • female patients, >=18 years of age; • primary HER2-negative operable breast cancer; • tumor >2cm in size; • ECOG performance status 0-1. Exclusion Criteria: • previous treatment for breast ...
View Page

7.  Study Posting (4519) Trial #121782, Breast Cancer, Sabadell, Spain
...frame: Throughout study Inclusion Criteria: • female patients, >=18 years of age; • primary HER2-negative operable breast cancer; • tumor >2cm in size; • ECOG performance status 0-1. Exclusion Criteria: • previous treatment for breast ...
View Page

8.  Study Posting (4519) Trial #148044, Breast Cancer, Málaga, Spain
...frame: Throughout study Inclusion Criteria: • female patients, >=18 years of age; • primary HER2-negative operable breast cancer; • tumor >2cm in size; • ECOG performance status 0-1. Exclusion Criteria: • previous treatment for breast ...
View Page

9.  Study Posting (4519) Trial #121737, Breast Cancer, Jaen, Spain
...frame: Throughout study Inclusion Criteria: • female patients, >=18 years of age; • primary HER2-negative operable breast cancer; • tumor >2cm in size; • ECOG performance status 0-1. Exclusion Criteria: • previous treatment for breast ...
View Page

10.  Study Posting (4519) Trial #121982, Breast Cancer, Córdoba, Spain
...frame: Throughout study Inclusion Criteria: • female patients, >=18 years of age; • primary HER2-negative operable breast cancer; • tumor >2cm in size; • ECOG performance status 0-1. Exclusion Criteria: • previous treatment for breast ...
View Page

11.  CenterWatch: Obstetrics/Gynecology Approved Drug Therapies
...Treatment for amenorrhea (abnormal cessation of menses), Approved May 1998 Xeloda ; Roche; Treatment for advanced breast cancer tumors, Approved April 1998 Drugs Approved in 1997 Alesse (100 mcg levonorgestrel/20 mcg ethinyl ...
View Page

12.  CenterWatch: Oncology Approved Drug Therapies
...Valstar ; Anthra Pharmaceuticals; Treatment for Bladder Cancer, Approved October 1998 Xeloda ; Roche; Treatment for advanced breast cancer tumors, Approved April 1998 Zofran ; GlaxoSmithKline; Treatment for postoperative vomiting and nausea in adults, Approved ...
View Page

13.  CenterWatch: Endocrinology Approved Drug Therapies
...Novartis; Treatment for acute organ transplant rejection, Approved May 1998 Xeloda ; Roche; Treatment for advanced breast cancer tumors, Approved April 1998 Zemplar ; Abbott Laboratories; Treatment of secondary hyperparathyroidism associated with chronic renal ...
View Page